¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Secure High Capacity Pad Misc"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • high pelvic position
    ³ôÀº°ñ¹ÝÀÚ¼¼
  • high polymer chemistry
    °íºÐÀÚÈ­ÇÐ
  • high potency
    1. °íÈ¿´É, °í¿ª°¡ 2. °íÀáÀç·Â
  • high power application
    °íÃâ·ÂÀû¿ë
  • high residue diet
    °íÀÜ·ùÀ½½Ä
  • high resolution
    °íÇØ»óµµ
  • high resolution computed tomography
    °íÇØ»óÄÄÇ»ÅÍ´ÜÃþÃÔ¿µ(¼ú)
  • high risk group
    °íÀ§Ç豺
  • high risk patient
    °íÀ§ÇèȯÀÚ
  • high signal
    °­ÇѽÅÈ£, °í½ÅÈ£
  • high signal intensity
    °í½ÅÈ£°­µµ
  • high spatial frequency algorithm
    °í°ø°£Á֯ļö¿¬»ê
  • high speed core cut biopsy
    °í¼ÓÁ߽ɺλý°Ë
  • high temperature sterilization
    °í¿Â¸ê±Õ
  • high tone deafness
    °íÀ½³­Ã»
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • high forceps
    °íÀ§Áý°Ô, À§ÂÊÁý°Ô
  • high frequency filter
    °íÁ֯İŏ£°³, °íÁÖÆÄ¿©°ú
  • high intensity proton flow
    °í°­µµ¾çÀÚÈ帧, °í°­µµ¾çÀÚÀ¯µ¿
  • high-output heart failure
    °í¹ÚÃâ½ÉÀå±â´É»ó½Ç, °í¹ÚÃâ½ÉÀåºÎÀü
  • high-pass filter
    °íÁÖÆÄÅë°ú°Å¸£°³, °íÁÖÆÄÅë°úÇÊÅÍ
  • high risk group
    °íÀ§Çèµµ±º
  • high insertion
    °íÀ§ºÎÂø
  • high resolution
    °íÇØ»ó
  • high signal
    °í½ÅÈ£
  • high speed
    °í¼Ó, °í¼Óµµ
  • high altitude polycythemia
    ³ôÀº°÷ÀûÇ÷±¸Áõ°¡Áõ
  • high dose rate
    °í¼±·®·ü
  • high dose rate intraluminal radiotherapy
    °í¼±·®À²°ü³»¹æ»ç¼±Ä¡·á
  • high energy radiation
    °í¿¡³ÊÁö¹æ»ç¼±
  • high field magnetic resonance scanner
    °íÀÚÀåÀÚ±â°ø¸í½ºÄ³³Ê
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • high frequency transducing lysate
    °íºóµµÇüÁúµµÀÔ ¿ë±Õ¹°
  • high frequency transduction
    °íºóµµÇüÁúµµÀÔ
  • high frequency ventilation = HFV
    °íºóµµÈ¯±â
  • high fusing porcelain
    °í¿ëµµÀç(ÍÔéÁÔ¶î§).
  • high insertion
    °íÀ§ºÎÂø
  • high lateral myocardial infarction
    È޾߼øÈ¯°íÀ§Ãøº®½É±Ù°æ»öÁõ(ÍÔêÈö°ÛúãýÐÉÌÛßáñø ).
  • high linear energy transfer radiation
    °í¼±Çü¿¡³ÊÁöÀüÀ̹æ»ç¼±
  • high lithotomy
    °íÀ§Àý¼®¼ú(°íÀ§Ã¼¼®¼ú).
  • high molecular weight kinin
    °íºÐÀÚ·®Å°´Ñ
  • high molecular weight kininogen
    °íºÐÀÚÁß·®Å°´Ï³ë°Õ
  • high myopia
    °íµµ±Ù½Ã(ÍÔöôÐÎãÊ).
  • high output failure
    °í¹ÚÃ⼺ ½ÉºÎÀü.
  • high output heart failure
    °í¹ÚÃ⼺ ½ÉºÎÀü(ÍÔÚÐõóàõãýÝÕîï).
  • high pelvic position =Trendelenburg p.
    Æ®·»µ¨·»ºÎ¸£Å©Ã¼À§(¡­ô÷êÈ).
  • high peroxidase cell
    °íÆä·Ï½Ã´Ù¾ÆÁ¦¼¼Æ÷
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • total lung capacity
    ÀüÆó¿ë·®(îïøËé»åÖ), Àü Æó±â·®(¡­Ñ¨åÖ).
  • unsaturated iron binding capacity
    ºÒÆ÷ȭö°áÇÕ´É(¡­ôÑÌ¿ùêÒö).
  • unsaturated iron binding capacity
    ºÒÆ÷ȭö°áÇÕ´É
  • unsaturated vitamin B12 binding capacity
    ºÒÆ÷È­ºñŸ¹Î B12 °áÇÕ´É
  • ventilatory capacity
    ȯ±â´É·Â(üµÑ¨Òöæ³).
  • vital capacity
    ÆóȰ·®, Æó¸ð¼¼°üÇ÷¾×·®(øËÙ¾á¬Î·úìäûåÖ)
  • vital capacity
    ÆóȰ·®
  • vital capacity
    ÆóȰ·®, Æó¸ð¼¼°üÇ÷¾×·®(øËÙ¾á¬Î·úìäûåÖ).
  • vital lung capacity
    ÆóȰ·®(øËüÀåÖ).
  • familial high density lipoprotein def
    °¡Á·¼º °íºñÁ߸®Æ÷´Ü¹éÁú°áÇÌ Áõ.
  • high altitude
    °í¼Ò
  • high altitude polycyth(a)emia
    °í¼Ò¼º ÀûÇ÷±¸Áõ°¡(Áõ)(Ë­ËÛËÛËøÌ´Ë´Ì¡?Ì¡) .
  • high altitude polycyth(a)emia
    °í¼Ò¼º ÀûÇ÷±¸Áõ°¡(Áõ)(ÍÔá¶àõîåúìϹñòÊ¥ñø) .
  • high altitude pulmonary edema
    °íÁöÆóºÎÁ¾.
  • high caloric diet
    °íÄ®·Î¸®½ÄÀÌ.
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 5
LAHC low affinity-high capacity
HCD health care delivery; heavy-chain disease; high-calorie diet; high-carbohydrate diet; homologous can...
HD Haab-Dimmer [syndrome]; Hajna-Damon [broth]; Hansen disease; hearing distance; heart disease; helix ...
HEP hemolysis end point; hepatoerythropoietic porphyria; high egg passage [virus]; high-energy phosphate...
HFD hemorrhagic fever of deer; high-fiber diet; high forceps delivery; hospital field director; human fa...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 5
GEC Galactose elimination capacity
IC Inspiratory Capacity
IVC Inspiratory Vital Capacity
MBC Maximal binding capacity
VmaxFRC Maximal flow at functional residual capacity
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • paramagnetic high susceptibility
    »óÀÚ¼º °íÀÚÈ­À²
  • super high field MR scanner
    ÃʰíÀÚÀå MR ½ºÄ³³Ê, Ãʰí ÀÚÀå Àڱ⠰ø¸í ½ºÄ³³Ê
  • tolerance to high altitude
    °í¼Ò ³»¼º
  • ultra high field MR scanner
    ÃʰíÀÚÀå Àڱ⠰ø¸í ½ºÄ³³Ê
  • ultra high speed handpiece
    Ãʰí¼Ó ÇÚµåÇǽº
    ÇÑ ½Ã°£¿¡ 100000-300000ȸÀüÀÇ ¼º´ÉÀ» °¡Áø ÇÚµåÇǽº.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
high altitude sickness A condition that results from the exposure to lower barometric pressure (lower oxygen concentration).
Synonym: acute mountain sickness.
(27 Sep 1997)
high blood cholesterol A condition where there is an above normal level of cholesterol in the bloodstream. A level of over 200 mg/dl is known to be a risk factor for heart disease. Less than 200 is desirable, 200 to 239 is considered borderline high, over 240 is considered high.
(27 Sep 1997)
high blood pressure <cardiology> Persistently high arterial blood pressure. Hypertension may have no known cause (essential or idiopathic hypertension) or be associated with other primary diseases (secondary hypertension).
This condition is considered a risk factor for the development of heart disease, peripheral vascular disease, stroke and kidney disease.
(29 Sep 1997)
high blood triglyceride <biochemistry> Elevation of triglycerides, a fatty substance found in the bloodstream. Normal triglyceride blood levels should be 10-150 milligrams per decilitre. Elevations of the triglyceride level (particularly in association with elevated cholesterol) have been correlated with the development of atherosclerosis, the underlying cause of heart disease and stroke.
Origin: Gr. Haima = blood
(27 Sep 1997)
high-bred Bred in high life; of pure blood.
Source: Websters Dictionary
(01 Mar 1998)
high-calorie diet A diet containing upward of 4,000 calories per day.
(05 Mar 2000)
high convex The segment of a sphere of short radius.
(05 Mar 2000)
high density lipoprotein <biochemistry> These lipoproteins acts to carry cholesterol in the bloodstream.
Raised high density lipoprotein levels have been correlated with a lower risk for heart disease. Less than 35 mg/dl is considered a positive risk factor for coronary artery disease, over 60 mg/dl is considered a negative risk factor (reduces your risk of heart disease).
Recent studies show a low high density lipoprotein level is the strongest predictor of cardiovascular death in women.
Acronym: HDL
(18 Nov 1997)
high dose tolerance The induction of tolerance by exposure to high doses of antigen.
(05 Mar 2000)
high-egg-passage vaccine Living Flury strain rabies virus at the 180th to 190th level egg passage (embryonate eggs), used for vaccination of cattle and cats, low-egg-passage (LEP) vaccine: at the 40th to 50th passage level, containing 103 to 104 mouse LD50; nonpathogenic in dogs but retains some pathogenicity for cattle and cats.
(05 Mar 2000)
high endothelial postcapillary venules Venule's in the lymph nodes, tonsils, and Peyer's patches that have a high-walled endothelium through which blood lymphocytes migrate into the lymphatic parenchyma.
(05 Mar 2000)
high enema An enema instilled high up into the colon.
Synonym: enteroclysis.
(05 Mar 2000)
high energy bond <chemistry> Chemical bonds that release more than 25kJ/mol on hydrolysis: their importance is that the energy can be used to transfer the hydrolysed residue to another compound. The risk in using the term is that students may think the bond itself is different in some way, whereas it is the compound that matters. Hydrolysis of creatine phosphate yields 42.7kJ/mol, of phosphoenolpyruvate, 53.2, ATP to ADP, 30.5: the latter is important because it shows that energetically the hydrolysis of creatine phosphate will suffice to reconstitute ATP, hence the use of creatine phosphate in muscle.
(18 Nov 1997)
high energy compounds Classically, a group of phosphoric esters whose hydrolysis takes place with a standard free energy change of -5 to -15 kcal/mol (or, -20 to -63 kJ/mol) (in contrast to -1 to -4 kcal/mol or, -4 to -17 kJ/mol) for simple phosphoric esters like glucose-6-phosphate or alpha-glycerophosphates), thus being capable of driving energy-consuming reactions in living cells or reconstituted cell-free systems; adenosine 5'-triphosphate, with respect to the beta-and gamma-phosphates, is the best known and is regarded as the immediate energy source for most metabolic syntheses. The general types are acid anhydrides, phosphoric esters of enols, phosphamic acid (R-NH-PO3H2) derivatives, acyl thioesters (e.g., of coenzyme A), sulfonium compound's (R3-S+), and aminoacyl esters of ribosyl moieties.
See: high energy phosphates.
(05 Mar 2000)
high energy particle generating unit A machine capable of providing highly energised radiation for the purposes of radiotherapy treatment.
(16 Dec 1997)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • high comedy
    (¿¬±âÀÇ ÀÍ»ì µûÀ§¿¡ ÁßÁ¡À» µÎÁö ¾Ê´Â)°í±ÞÈñ±Ø
  • high command
    ÃÖ°í »ç·ÉºÎ
  • high commissioner
    (½Ä¹ÎÁöÀÇ)°íµî ÆÇ¹«°ü !
  • high crime
    Áß´ëÇÑ ¹üÁË(´ëÅë·É ±âŸ ÇàÁ¤°üÀÇ ÅºÇÙ ÀÌÀ¯°¡ µÇ´Â ÆÄ·ÅÄ¡ ¹üÁË)
  • high day
    ÃàÁ¦ÀÏ
  • high day
    ÃàÁ¦ÀÏ;°æÃàÀÏ
  • high explosive
    °í¼º´É Æø¾à
  • high faluting
    °úÀåµÈ (¸»)
  • high farming
    Áý¾à³ó¾÷
  • high fashion
    (ÀǺ¹ÀÇ)ÃֽŠÀ¯Çà ½ºÅ¸ÀÏ(µðÀÚÀÎ);ÇÏÀÌ ÆÐ¼Ç;=haute couture
  • high feeding
    ¹Ì½Ä
  • high fidelity
    (¶óµð¿À,ÀüÃàÀÌ ¿øÀ½À» Àç»ýÇÏ´Â)°íÃæ½Çµµ;ÇÏÀÌÆÄÀÌ
  • high finance
    °Å´ëÇÏ°í º¹ÀâÇÑ ±ÝÀ¶ °Å·¡
  • high frequency
    °íÁÖÆÄ;´ÜÆÄ
  • high frontier
    ¿ìÁÖÀü¼±
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 5
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 5
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 5
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 5
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 5
ÅëÇÕ°Ë»ö ¿Ï·á